Analysis of Pharmaceutical Impurities

Significance of the Topic

Montelukast is a widely prescribed leukotriene receptor antagonist used to manage asthma and allergic rhinitis. Ensuring the purity of montelukast API is essential for patient safety and regulatory compliance. Profiling trace-level impurities supports drug quality and aids in meeting stringent pharmacopeial standards.

Objectives and Study Overview

This application note demonstrates a rapid and reliable reversed-phase LC–MS method for the separation and detection of montelukast and six related impurities. The study aims to optimize chromatographic conditions and mass spectrometric parameters to achieve sensitive impurity profiling suitable for pharmaceutical quality control.

Methodology and Instrumentation

Chromatography was performed on a Shim-pack Scepter Phenyl-120 column (100 mm × 3.0 mm, 1.9 µm particle size) using a Nexera X3 UHPLC system. A gradient of 0.15% formic acid in water (mobile phase A) and 0.1% formic acid in acetonitrile (mobile phase B) was applied at 0.5 mL/min: 45% B (0–3 min) to 75% B (3–13 min), then return to 45% B (13.01–18 min). Column temperature was maintained at 30 °C and injection volume was 10 µL of 1000 mg/L solution.
Mass spectrometric detection was carried out on an LCMS-2050 instrument with ESI/APCI dual ionization in positive and negative modes. MS parameters included a scan range of m/z 400–800, nebulizing gas flow at 2.0 L/min, drying gas at 5.0 L/min, heating gas at 7.0 L/min, DL temperature 200 °C, desolvation temperature 450 °C, and interface voltage set to +3.0 kV (positive) / −2.0 kV (negative). A SPD-M40 PDA detector monitored the analytes at 238 nm.

Main Results and Discussion

The optimized method achieved baseline separation of montelukast and six impurities within 18 minutes. Reproducible retention times and consistent peak shapes were observed under the phenyl-stationary phase, highlighting its selectivity for aromatic and polar degradation products. Dual-mode ionization enhanced detection coverage, enabling the identification of impurities with diverse chemical characteristics. Sensitivity was sufficient to detect impurities at trace levels, supporting stringent quality thresholds.

Benefits and Practical Applications

• High throughput impurity profiling in routine QC laboratories.
• Robust separation using a phenyl-phase column for complex matrices.
• Comprehensive detection via combined ESI/APCI modes.
• Compliance with regulatory guidelines for impurity quantification.

Future Trends and Opportunities

Advancements in high-resolution mass spectrometry may further improve impurity identification and structure elucidation. Miniaturized UHPLC systems and automated data processing workflows are expected to enhance laboratory efficiency. Integration of chemometric tools can support predictive impurity profiling during drug development stages.

Conclusion

The presented LC–MS method using Shim-pack Scepter Phenyl-120 and NX3/LCMS-2050 platforms offers a fast, sensitive, and reliable solution for monitoring montelukast impurities. Its robustness and compatibility with regulatory requirements make it a valuable asset for pharmaceutical quality assurance.

References

• Application News 01-00443 (JP, ENG), Shimadzu Corporation, 2024.